FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207066590> ?p ?o ?g. }

• W4207066590 endingPage "103805" @default.
• W4207066590 startingPage "103805" @default.
• W4207066590 abstract "Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what other factors affect responsiveness.We measured IgA, IgG and IgM levels against SARS-CoV-2 spike (S) and nucleocapsid (N) antigens from the wild-type and S from the Alpha, Beta and Gamma variants of concern, after BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccination in a cohort of health care workers (N=578). Neutralizing capacity and antibody avidity were evaluated. Data were analyzed in relation to COVID-19 history, comorbidities, vaccine doses, brand and adverse events.Vaccination induced robust IgA and IgG levels against all S antigens. Neutralization capacity and S IgA and IgG levels were higher in mRNA-1273 vaccinees, previously SARS-CoV-2 exposed, particularly if symptomatic, and in those experiencing systemic adverse effects (p<0·05). A second dose in pre-exposed did not increase antibody levels. Smoking and comorbidities were associated with 43% (95% CI, 19-59) and 45% (95% CI, 63-18) lower neutralization, respectively, and 35% (95% CI, 3-57%) and 55% (95% CI, 33-70%) lower antibody levels, respectively. Among fully vaccinated, 6·3% breakthroughs were detected up to 189 days post-vaccination. Among pre-exposed non-vaccinated, 90% were IgG seropositive more than 300 days post-infection.Our data support administering a single-dose in pre-exposed healthy individuals as primary vaccination. However, heterogeneity of responses suggests that personalized recommendations may be necessary depending on COVID-19 history and life-style. Higher mRNA-1273 immunogenicity would be beneficial for those expected to respond worse to vaccination and in face of variants that escape immunity such as Omicron. Persistence of antibody levels in pre-exposed unvaccinated indicates maintenance of immunity up to one year.This work was supported by Institut de Salut Global de Barcelona (ISGlobal) internal funds, in-kind contributions from Hospital Clínic de Barcelona, the Fundació Privada Daniel Bravo Andreu, and European Institute of Innovation and Technology (EIT) Health (grant number 20877), supported by the European Institute of Innovation and Technology, a body of the European Union receiving support from the H2020 Research and Innovation Programme. We acknowledge support from the Spanish Ministry of Science and Innovation and State Research Agency through the Centro de Excelencia Severo Ochoa 2019-2023 Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. L. I. work was supported by PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation. Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400008C). The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript." @default.
• W4207066590 created "2022-01-26" @default.
• W4207066590 creator A5002148348 @default.
• W4207066590 creator A5008272570 @default.
• W4207066590 creator A5012099675 @default.
• W4207066590 creator A5017918342 @default.
• W4207066590 creator A5018028724 @default.
• W4207066590 creator A5028532677 @default.
• W4207066590 creator A5031342151 @default.
• W4207066590 creator A5031674089 @default.
• W4207066590 creator A5039681712 @default.
• W4207066590 creator A5039754621 @default.
• W4207066590 creator A5042536002 @default.
• W4207066590 creator A5042597223 @default.
• W4207066590 creator A5045630538 @default.
• W4207066590 creator A5047377569 @default.
• W4207066590 creator A5049923100 @default.
• W4207066590 creator A5050181482 @default.
• W4207066590 creator A5053726558 @default.
• W4207066590 creator A5053853665 @default.
• W4207066590 creator A5060193788 @default.
• W4207066590 creator A5060244419 @default.
• W4207066590 creator A5061858171 @default.
• W4207066590 creator A5062503280 @default.
• W4207066590 creator A5066717168 @default.
• W4207066590 creator A5067810621 @default.
• W4207066590 creator A5070289351 @default.
• W4207066590 creator A5073496723 @default.
• W4207066590 creator A5073645769 @default.
• W4207066590 creator A5084845274 @default.
• W4207066590 creator A5086187964 @default.
• W4207066590 date "2022-01-01" @default.
• W4207066590 modified "2023-10-17" @default.
• W4207066590 title "Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers" @default.
• W4207066590 cites W2093274439 @default.
• W4207066590 cites W2944434778 @default.
• W4207066590 cites W2990427812 @default.
• W4207066590 cites W3025631553 @default.
• W4207066590 cites W3105937899 @default.
• W4207066590 cites W3111255098 @default.
• W4207066590 cites W3119780353 @default.
• W4207066590 cites W3121008609 @default.
• W4207066590 cites W3123108673 @default.
• W4207066590 cites W3126729284 @default.
• W4207066590 cites W3131072190 @default.
• W4207066590 cites W3133819496 @default.
• W4207066590 cites W3136570200 @default.
• W4207066590 cites W3137469790 @default.
• W4207066590 cites W3142193311 @default.
• W4207066590 cites W3146894320 @default.
• W4207066590 cites W3155262144 @default.
• W4207066590 cites W3156150675 @default.
• W4207066590 cites W3158276912 @default.
• W4207066590 cites W3159191704 @default.
• W4207066590 cites W3159733845 @default.
• W4207066590 cites W3164711393 @default.
• W4207066590 cites W3174334961 @default.
• W4207066590 cites W3174829503 @default.
• W4207066590 cites W3174875956 @default.
• W4207066590 cites W3178772652 @default.
• W4207066590 cites W3182514649 @default.
• W4207066590 cites W3182882252 @default.
• W4207066590 cites W3183658092 @default.
• W4207066590 cites W3185915480 @default.
• W4207066590 cites W3190192691 @default.
• W4207066590 cites W3190750829 @default.
• W4207066590 cites W3192691285 @default.
• W4207066590 doi "https://doi.org/10.1016/j.ebiom.2021.103805" @default.
• W4207066590 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35032961" @default.
• W4207066590 hasPublicationYear "2022" @default.
• W4207066590 type Work @default.
• W4207066590 citedByCount "50" @default.
• W4207066590 countsByYear W42070665902021 @default.
• W4207066590 countsByYear W42070665902022 @default.
• W4207066590 countsByYear W42070665902023 @default.
• W4207066590 crossrefType "journal-article" @default.
• W4207066590 hasAuthorship W4207066590A5002148348 @default.
• W4207066590 hasAuthorship W4207066590A5008272570 @default.
• W4207066590 hasAuthorship W4207066590A5012099675 @default.
• W4207066590 hasAuthorship W4207066590A5017918342 @default.
• W4207066590 hasAuthorship W4207066590A5018028724 @default.
• W4207066590 hasAuthorship W4207066590A5028532677 @default.
• W4207066590 hasAuthorship W4207066590A5031342151 @default.
• W4207066590 hasAuthorship W4207066590A5031674089 @default.
• W4207066590 hasAuthorship W4207066590A5039681712 @default.
• W4207066590 hasAuthorship W4207066590A5039754621 @default.
• W4207066590 hasAuthorship W4207066590A5042536002 @default.
• W4207066590 hasAuthorship W4207066590A5042597223 @default.
• W4207066590 hasAuthorship W4207066590A5045630538 @default.
• W4207066590 hasAuthorship W4207066590A5047377569 @default.
• W4207066590 hasAuthorship W4207066590A5049923100 @default.
• W4207066590 hasAuthorship W4207066590A5050181482 @default.
• W4207066590 hasAuthorship W4207066590A5053726558 @default.
• W4207066590 hasAuthorship W4207066590A5053853665 @default.
• W4207066590 hasAuthorship W4207066590A5060193788 @default.
• W4207066590 hasAuthorship W4207066590A5060244419 @default.
• W4207066590 hasAuthorship W4207066590A5061858171 @default.
• W4207066590 hasAuthorship W4207066590A5062503280 @default.

• next